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Context: Hepatitis B virus (HBV) infection is a cause of chronic liver disease, causing cirrhosis and hepatocellular carcinoma, 
and pregnant women are not spared. Perinatal transmission is a significant way that the disease is spread from mother to 
children who will eventually become adults and chronic carriers. This study sought to determine the burden of the disease 
among pregnant women.
Aims: To estimate the prevalence and investigate possible factors associated with HBV infection among pregnant women 
attending antenatal clinics in DASH, Lafia.
Settings and Design: A hospital‑based descriptive cross‑sectional survey conducted at the Obstetrics and Gynecology 
Department of DASH, Lafia, Nasarawa
Methods and Material: Around 200 pregnant women who attended the ANC clinic were consecutively enrolled, their venous 
blood samples collected, and hepatitis B profile was carried out using commercially available rapid chromatographic kits
Statistical Analysis Used: Data were collected by trained data collectors using a proforma, then entered into a predesigned 
program in the Epi‑info version 3.5.4 (CDC, Atlanta, Georgia, USA) and analyzed.
Results: The seroprevalence of HBV infection was high (8%) and there were no statistically significant associations between 
the infection and the investigated sociodemographic and other risk factors.
Conclusions: The study showed that HBV is hyperendemic in this region, and antenatal screening for this virus is desirable 
to avert its sequelae in both mothers and their newborn babies.
Key words: Antenatal; hepatitis B virus; Lafia.
Introduction
Hepatitis B virus (HBV) infection primarily affects the liver 
and causes hepatocellular necrosis and inflammation-causing 
both acute and chronic diseases.[1] It has been identified as 
a serious public health problem worldwide and is reported 
to be 50–100 times more contagious than HIV.[2,3] In 2015, 
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an estimated 257 million people were chronically infected 
with HBV worldwide resulting in 1.34 million deaths, a figure 
higher than that caused by HIV.[4] Most of the deaths from 
hepatitis B are from cirrhosis and hepatocellular carcinoma. 
About 43% of liver cancer is due to late testing and treatment 
of HBV infection.[4,5]
The most common transmission of the virus is from a pregnant 
mother to a child, as well as through contact with blood or 
other body fluids.[1] Pregnant mothers who test positive for 
both hepatitis B surface antigen (HBsAg) and hepatitis B 
e antigen (HBeAg) have a 70–90% risk of transmitting the 
infection to their newborn infants and about 10–40% risk if 
they test positive for only HBsAg.[6,7] The risk of becoming 
a chronic hepatitis B infection carrier is 95% for infections 
acquired during the perinatal period compared with only 5% 
for those acquired during adulthood.[8,9]
Viral hepatitis during pregnancy is also associated with a 
high risk of maternal complications, as well as a high rate of 
causing fetal and neonatal hepatitis via vertical transmission, 
which can have serious effects on the neonate, leading 
to impaired mental and physical health later in life.[10] 
Unfortunately, routine antenatal screening for HBV infection 
is not done in many Nigerian hospitals.[11]
The African sub-region is second only to the Western Pacific 
region, in terms of number of people living with this virus.[12] 
The prevalence of HBsAg in the normal population in Nigeria 
is thought to be high and ranges from 2.7 to 13.3%.[13,14]
Despite this, no national study on the seroprevalence of 
HBV has been done for the Nigerian population as well as in 
pregnant women. Most individual studies done were only 
on seroprevalence of HBsAg, with a few identifying other 
serological markers of HBV infection.[15]
In a systematic review and meta-analysis of the prevalence 
of HBV infection in Nigeria done in 2015, Musa et al. had 
reported a pooled prevalence of 14.1% in pregnant antenatal 
women in Nigeria highlighting the fact that Nigeria is a 
hyperendemic region for HBV infection.[16]
Justification of the study
Despite Nigeria being classified among countries highly 
endemic for viral hepatitis and variations in prevalence rates 
across the country, routine screening for HBV infection is 
currently not incorporated as part of the booking investigations 
in our hospital. The paucity of data concerning the prevalence 
of HBV infection in pregnant women in our facility and the 
state has also made it difficult to make recommendations to 
this effect. This study will, therefore, help to determine the 
prevalence of HBV infection and associated factors among 
pregnant women attending antenatal care clinics in DASH 
Lafia, Nasarawa state Nigeria, to help generate information 
that could be used to make recommendations and monitor 
the trend of the disease in this area.
Aim of Study
To estimate the prevalence and investigate possible factors 
associated with HBV infection among pregnant women 
attending antenatal clinics in DASH, Lafia.
Specific objectives
•	 To	determine	 the	prevalence	of	HBV	 infection	among	
these pregnant women
•	 To	investigate	the	associated	sociodemographic	and	risk	




This study was conducted at the Obstetrics and Gynecology 
Department of Dalhatu Araf Specialist Hospital, Lafia, 
Nasarawa State between September 2017 to December 2017. 
The hospital is a specialist training and referral center located 
in Lafia town, the capital of Nasarawa state in Nigeria. The 
department has two teams A and B which conduct antenatal 
clinics on Mondays and Fridays, respectively. Averages of 130 
women are seen on each clinic day by each of the teams.
Study population
All pregnant women attending ANC at Dalhatu Araf Specialist 








The study was a hospital-based descriptive cross-sectional 
survey.
Sample size estimation
The sample size was calculated using the formula for 
prevalence studies.[17]
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Where N = minimum sample size
Z = statistic for the level of confidence at 95% is 1.96
P = expected prevalence
D = precision of 5% is 0.05
A prevalence rate of 11% was reported among pregnant 
women attending antenatal clinics in Makurdi, a neighboring 
town.[18] Hence the value P = 0.11 was used to calculate 
sample size for the study.
Thus, n = 1.962 × 0.11 (1-0.11)/0.052 = 150
Giving allowance for a 10% attrition rate for non-responders 
or improperly filled questionnaires, the minimum sample size 
for the study was therefore 165. As this was the minimum 
sample size, 200 women were recruited for the study.
Sample selection
On every antenatal day, the pregnant women were given 
health talk on infectious diseases in pregnancy including HBV 
infections and the need to know their status. Only consenting 
attendees were recruited and included in the study. According 
to the sequence of their registration, they were allowed to 
enter into the ANC room for routine follow-up care one by 
one. The purpose of the study was explained to each subject, 
and she was asked to participate voluntarily in the study. To 
avoid recruiting subjects multiple times, a unique mark was 
put on cards of all enrolled mothers. Accordingly, pregnant 
women who attended the ANC clinic were consecutively 
enrolled until the desired sample size was attained. 
Information on sociodemographic and other pertinent data 
was collected by trained data collectors using a proforma, 
then entered into a predesigned program in the Epi-info 
version 3.5.4 (CDC, Atlanta, Georgia, USA) and analyzed.
Blood sample collection, processing, and procedure for 
detecting HBsAg
Around 3mL of venous blood was collected using a 
properly labelled plain bottle by an experienced laboratory 
technologist from each study participant under the aseptic 
procedure. Afterward, the blood was allowed to clot at room 
temperature and the serum separated by centrifugation. Part 
of the serum was collected and analyzed.
Hepatitis B profile was done using commercially available rapid 
chromatographic immunoassays for the qualitative detection 
of HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb (ACRO BIOTECH 
Inc, Rancho Cucamonga, CA, USA). The qualitative assay 
was performed using one-step test strips for the detection 
of hepatitis B profile in serum samples. The test was within 
few minutes of specimen collection and separation. The 
immunochromatographic reaction was allowed to take place 
within a few minutes and the result read exactly 15 min after.
The hepatitis B profile assay has manufacturer reported 
diagnostic specificity, sensitivity, and accuracy. The results 
of the test were reported as positive, negative or invalid 
accordingly. For each invalid test, there was a repeat with 
a new strip.
Ethical considerations
Ethical clearance was obtained from the DASH Ethics Review 
Committee. All study participants were informed about the 
study and assured about confidentiality, protection, and 
anonymity of data. Written consent was obtained from each 
study participant before data collection as evidence to show 
that they participated voluntarily in the study.
Results
Two hundred women gave consent and had their data 
taken for analysis. The mean age of the women was 
27.1 ± 6.2 (range 17–45 years) but that of hepatitis B infected 
women was 26.0 ± 4.9 and that of the noninfected women 
27.0 ± 6.2. Although most of the women were within the 
age range of 25–29 years (31.5%), hepatitis B infection was 
found to be highest among those in the 30–34 years age 
group (50.0%) followed by those in the 25–29 years age group 
who had 25% as shown in Table 1.
The mean parity of the women was 2.6 ± 2.4, but that 
of the hepatitis B infected women was 3.7 ± 2.7, and it 
was 2.5 ± 2.3 for the noninfected group. Most of them 
were urban dwellers 178 (89%). Most of the respondents 
were married women 196 (98%). A majority of the women 
had at least a primary education, leaving 57 (28.5%) 
with no formal education. However, more than half of 
Table 1: Age group and hepatitis B infectivity
Age group 
(years)
Frequency Percentage (%) Hepatitis B infection
15‑19 14 7 1 (6.2%)
20‑24 53 26.5 3 (18.8%)
25‑29 63 31.5 4 (25.0%)
30‑34 39 19.5 8 (50.0%)
35‑39 24 12 0
40‑44 6 3 0
≥45 1 0.5 0
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Table 2: Sociodemographic characteristics for hepatitis B virus 
(HBV) infection
Variable HBV Positive HBV Negative P
Mean age±SD (years) 26.0±4.9 27.0±6.2 0.79
Mean Parity±SD 3.7±2.7 2.5±2.3 0.07
Marital status
Married 16 (8.2%) 180 (91.8%)
Single 4 (100%) 0.71
Educational level
None 6 (10.5%) 51 (89.5%)
Primary 3 (12.0%) 22 (88.0%)
Secondary 5 (7.6%) 61 (92.4%)
Tertiary 2 (3.8%) 50 (91.7%) ‑
Occupation
Unemployed 12 (10.6%) 101 (89.4%)
Student ‑ 9 (100%)
Self‑employed 2 (3.7%) 52 (96.3%)
Government employed 2 (8.3%) 22 (91.7%) ‑
Ethnicity
Hausa 3 (5.0%) 57 (95.0%)
Eggon 2 (7.1%) 26 (92.9%)
Kanuri 4 (16.0%) 21 (84.0%)
Alago 1 (5.3%) 18 (94.7%)
Fulani ‑ 15 (100%)
Gwadara 1 (10%) 9 (90%)
Igbo ‑ 10 (100%)
Others 5 (15.2%) 28 (84.8%)
Religion
Islam 12 (7.8%) 141 (92.2%)
Christianity 4 (8.7%) 42 (91.3%)
Traditional ‑ 1 (100%)
Table 3: Immunological test/Prevalence of hepatitis B infection
Category Immunology Frequency Prevalence%
Infected HBsAg    +ve 16 8
HBcAb    +ve
HBsAb    −ve
Immune from HBsAg    −ve 24 12
Hep B vaccination HBcAb    −ve
HBsAb    +ve
Immune from HBsAg    −ve 0 0
natural infection HBcAb    +ve
HBsAb    +ve
Susceptible patients HBsAg    −ve 127 63.5
HBcAb    −ve
HBsAb   −ve
the respondents (56.5%) were unemployed. The sample 
population comprised mostly of women of the Hausa 
tribe (30%) and Islam was the predominant religion identified. 
Other sociodemographic characteristics are as shown below 
in Table 2.
The result of the immunological test and the prevalence of 
the HBV are shown in Table 3. Sixteen of the women were 
found to be infected (positive for HBsAg and HBcAb), giving 
a prevalence rate of 8%. Twenty four (12%) of the women 
showed evidence of immunity to hepatitis B vaccination and 
127 (63.5%) of these women are susceptible to infection from 
the table as shown. No woman tested positive for HBeAg.
Table 4 highlights the other associated risk factors, with 
ear piercing, scarifications, and TBA home delivery being 
commonest among those who tested positive for HBsAg.
Discussion
The prevalence of hepatitis B infection from our study 
population was found to be 8% and there was no statistically 
significant association found between hepatitis B infection 
and the investigated sociodemographic and other risk factors.
The HBV seroprevalence found in this study is slightly higher 
than the finding of 7.2% from a recent study in the same 
institution by Audu and her colleagues.[19] The difference 
between the two studies could be from the study design and 
population, as that was a retrospective study in both males 
and non-pregnant females who were accessing antiretroviral 
drugs in the hospital. Conversely, the finding is lower than 
a previous study carried out in a different facility in another 
part of the state which found a prevalence of 11%.[20] That 
study by Akyala and his colleagues was carried out in both 
males and non-pregnant females, and this difference in the 
study population may also explain the lower prevalence of 
our study. Nonetheless, the seroprevalence from our study 
showed that this study group falls into the category of high 
endemicity as defined by the WHO[21] and efforts need to be 
geared towards incorporating routine screening for HBV in 
the antenatal clinic as inadequate coverage for testing and 
treatment has been identified as a most important gap in 
global efforts toward eliminating viral hepatitis by 2030.[4]
Besides, vaccination of susceptible individuals is another strategy 
that will help in eliminating viral hepatitis. From our study, only 
24 (12%) out of the women showed any serological evidence of 
immunity from vaccination. Likewise, 127 (63.5%) of the women 
were found to be susceptible to hepatitis B infection from the 
serological profile and had not had prior vaccination. Vaccination 
against HBV in Nigeria has been sub-optimal because of poor 
funding by the government and community misconceptions 
about the vaccines.[22-24] Therefore, addressing these issues will 
require political will, community education and re-orientation 
to change the narrative and allow better coverage.
When the association between HBV infection and 
sociodemographic factors was investigated, none was found 
to be significantly associated with the occurrence of infection. 
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In the study by Nongo and his colleagues,[25] they reported 
that the majority of the population that tested positive were 
within the age range of 25–29 years. This is unlike in our 
study were we found that the majority (50%) of the hepatitis 
B infected women are within the age group of 30–34 years.
Besides, evaluating the association of hepatitis B infection 
with other risk factors showed that three risk factors were 
outstanding among the seroprevalence group and these 
include: ear piercing, TBA home delivery, and scarifications. 
However, none of them was found to be statistically 
significant. Public enlightenment and awareness campaigns 
should be put in place to educate women on the dangers of 
such practices. Similarly, the other risk factors such as the 
history of tattoos or traditional uvulectomy/tonsillectomy, 
number of sexual partners, history of blood transfusion, 
recreational drug use or parity did not reveal any significant 
statistical relationship with HBsAg positivity.
Conclusion
The prevalence of hepatitis B infection is high in this study 
population but there was no significant association found 
between the occurrence of infection and the evaluated 
sociodemographic and other risk factors.
We recommend a regime of routine antenatal screening for 
this infection among pregnant women to enable identification 
of cases and appropriate management of the mother and 
newborn as we join the global effort to eliminate the disease 
and hopefully its complications by 2030.
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Table 4: Risk factors
Variable HBsAg HBsAg Odds 95% CI P
Positive Negative ratio
Blood Transfusion  
Yes 3 (13%) 20 (87%) 1.9 0.5‑7.2 0.27
No 13 (7.3%) 164 (92.7%)
HIV status
Yes 2 (15.4%) 11 (84.6%) 0.4 0.1‑2.2 0.28
No 14 (7.5%) 173 (92.5%)  
Ear piercing
Yes 16 (8.3%) 176 (91.7%) ‑ ‑ 0.51
No 0 (0%) 8 (100%)
Nose Piercing
Yes 5 (11.1%) 40 (88.9%) 1.6 0.5‑5.0 0.28
No 11 (7.1%) 144 (92.9%)
Tattoo
Yes 3 (9.1%) 30 (90.9%) 1.2 0.3‑4.4 0.51
No 13 (7.8%) 154 (92.2%)
Scarification
Yes 11 (10.2%) 97 (89.8%) 2.0 0.7‑5.9 0.17
No 5 (5.4%) 87 (94.6%)
Uvulectomy/Tonsillectomy
Yes 4 (7.0%) 53 (93.0%) 0.8 0.3‑2.7 0.50
No 12 (8.4%) 131 (91.6%)
TBA Home delivery
Yes 10 (12.0%) 73 (88%) 2.5 0.9‑7.3 0.04
No 6 (5.1%) 111 (94.9%)
Recreational (IV) drugs
Yes 0 (0%) 3 (100%) ‑ ‑ 0.78
No 16 (8.1%) 181 (91.9%)
Sexual partners
≥2 1 (6.7%) 14 (93.3%)
1 15 (8.1%) 170 (91.9%) 1.2 0.2‑10.1 0.66
Parity
≥5 5 (11.9%) 37 (88.1%)
0‑4 11 (7%) 147 (93%) 1.8 0.6‑5.5 0.22
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